Kyriakopoulos, C. E., Pachynski, R. K., Eickhoff, J. C., Tonelli, T. P., Jeon, D., McNeel, D. G.

Phase 2 trial of pTVG-HP {+/-} pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

24 de April de 2026 by Kyriakopoulos, C. E., Pachynski, R. K., Eickhoff, J. C., Tonelli, T. P., Jeon, D., McNeel, D. G.

Background
We previously reported a trial using pembrolizumab with a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) in patients with metastatic castration-resistant prostate cancer (mCRPC). Favorable clinical outcomes were associated with T…